ClinicalTrials.gg
TerminatedNCT01833845Updated Aug 28, 2014Results posted

Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

A Phase 1/2 interventional study of Ribavirin and Hydroxychloroquine in Hepatitis C, sponsored by BioLineRx, Ltd.. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-28.

Sponsored by BioLineRx, Ltd. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
due to failure to recruit subjects

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
164th of 174
4 · median 78
Started
2013
with 10 others
Phase 1/2
6 of 174
none open now
Registered
115th of 174
by date

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 164th largest by enrollment, is one of 11 that started in 2013, is one of 6 in phase 1/2, and was the 115th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

Proof-of Concept, Open-Label, Two-Stage Study without Direct Individual Benefit The proposed study design consists of two treatment periods and one treatment arm. Treatment Period 1 involves the administration of RBV monotherapy for a period of 8 weeks and Treatment Period 2 involves administration of up to 16 weeks combination therapy with RBV plus HCQ.

Read the detailed description

Patients who provide their informed consent and conform to all the inclusion and none of the exclusion criteria will be enrolled into the study and will receive RBV monotherapy for 8 weeks. Subjects will receive weight-based doses (1000 mg/day administered BID [twice daily] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.

During Treatment Period 2, subjects will receive HCQ 575 mg administered as a single tablet once daily (QD), in addition to continuing the same dose of RBV that was administered during Treatment Period 1, as combination therapy for up to 16 weeks.

Subjects will undergo regular blood sampling throughout Treatment Periods 1 and 2 to measure viral response (HCV RNA). Safety will be assessed throughout the study by collection of adverse event (AE) and concomitant medication data, and routine monitoring of laboratory safety tests, vital signs and 12-lead electrocardiograms (ECG).

Subjects will have their viral response tested following 12 weeks of combination therapy; those who show \< 1 log decline in viral load during the combination therapy will have the opportunity to withdraw and transfer to standard of care (SoC) treatment following performance of the "End of Study Treatment" visit.

On completion of study treatment, subjects will be allowed to transfer immediately to SoC treatment in order to maximize the benefit of any reduced viral load resulting from combination therapy with RBV plus HCQ. Subjects will attend the clinical site for an "End of Study Treatment" visit within 2 weeks of the final dose of combination treatment with RBV plus HCQ during which they will undergo a final measurement of HCV RNA, safety assessments as described above and a full physical and ophthalmic examination. The "End of Study Treatment" visit may take place on the same day as the final study visit at week 24.

In the event of subjects achieving viral undetectability during combination therapy, the relevant subjects may be administered additional combination therapy to achieve a total of 24 weeks of viral undetectability. If combination dosing with RBV plus HCQ continues for more than 16 weeks, subjects will continue to attend the clinical site and undergo assessment of safety and viral load at the discretion of the Investigator. However, treatment beyond 16 weeks of combination therapy will be considered compassionate use and will not be considered part of the study. In these subjects, the "End of Study Treatment" visit will take place no more than 2 weeks after the Week 24 visit.

03

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • HCV
  • Hepatitis C
  • Hep-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18.
  2. Subjects diagnosed to have positive antibodies.
  3. Subject is diagnosed to have detectable HCV RNA by PCR.
  4. FibroTest or FibroScan or liver showing a METAVIR score ≤ F2 and/or

    ≤ A2 within 2 years of the screening visit.

  5. Subject is a non-responder (null or partial ) OR following prior Peg-IFN and RBV based treatment lasting for at least 12 consecutive weeks.
  6. count greater than or equal to 100,000 cells/mm3.
  7. (ANC) greater than or equal to 1500 cells/mm3.
  8. Subjects able to comprehend and give written for participation in this study.
  9. Women of and all men must agree to use an approved form of (e.g., oral, transdermal patch, implanted contraceptives, intrauterine device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and for the duration of study participation through 7 months after the last dose of study medication. Confirmation that the female patient is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for or surgically sterilized women.
  10. Subject is willing to be treated and commit to all visits

Exclusion criteria

Exclusion Criteria:

  1. or to one of the study drugs (HCQ or RBV).
  2. Patient has anemia (male \<13 g/dL; female \<12 g/dL), elevated and/or AST >10 x or elevated creatinine (>1.5 mg/dL).
  3. Concomitant liver disease other than : alcoholic liver disease, hepatitis, Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency.
  4. Decompensated cirrhosis ( >A).
  5. Ongoing hepatocellular carcinoma (suggestive imaging study or alpha-fetoprotein (AFP) >50 ng/mL).
  6. or (HIV1 or HIV2) co-infection.
  7. abnormalities on screening or baseline 12-lead ECG, e.g.,

    • (QTcB or QTcF > 450 ms in males and > 470 ms in females);
    • Notable resting bradycardia (HR \< 40 bpm);
    • Any other significant abnormality suggestive of structural heart disease.
  8. Family history of congenital long QT syndrome.
  9. Clinically significant abnormalities on ophthalmic examination.
  10. Major uncontrolled psychiatric illness. Minor or situational depressions are allowed.
  11. History of hemoglobinopathy (e.g., thalassemia) or any other cause of or tendency to hemolysis (e.g., G-6-PD deficiency).
  12. Active illicit drug or alcohol abuse.
  13. Serious co-morbid conditions such as: heart failure, significant coronary heart disease, , poorly controlled diabetes, autoimmune disorders and any malignant diseases (except in situ carcinomas or basal cell carcinoma) in the previous 5 years.
  14. Patients with chronic renal insufficiency, \< 50 mL/minute and/or undergoing haemodialysis.
  15. Patients with porphyria or psoriasis.
  16. Ongoing concomitant treatment with azathioprine, digoxin or medications known to prolong QT interval.
  17. History of organ transplantation.
  18. Pregnancy, breast-feeding or unwillingness to practice double or abstinence by the subject of or partner.
  19. Concurrent participation in any other clinical study or within 180 days 20.Patients with inability to communicate well with the Investigators and staff (i.e., language problem, poor mental development or impaired cerebral function) or any other condition that in the opinion of the Investigator will place the patient at risk or prevent protocol compliance.

    -

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Ribavirin+HCQ

    Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).

    Drug: Ribavirin · Drug: Hydroxychloroquine

Interventions

  • weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.

    Also known as: RBV

  • subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)

    Also known as: HCQ

06

What researchers measure

Primary outcomes

  1. Efficacy

    To evaluate the effect of 16-week combination therapy with RBV plus HCQ following 8 weeks of monotherapy with RBV in HCV-infected patients.

    Time frame: 24 weeks

  2. Safety: Number of Participants With Adverse Events

    Safety was assessed throughout study by collection of adverse event and concomitant medication data, and routine monitoring of lab safety tests, physical exams, ophthalmic examination, vital signs and 12 lead electrocardiograms.

    Time frame: all 24 weeks

Secondary outcomes

  1. Efficacy

    To evaluate the efficacy of 8 weeks monotherapy with RBV in HCV-infected patients.

    Time frame: 8 weeks

07

Results

Posted Aug 28, 2014

Participant flow

Participant flow — Overall Study
MilestoneRibavirin+HCQ
Started4
Completed4
Not completed0

Outcome measures

PrimaryEfficacy

To evaluate the effect of 16-week combination therapy with RBV plus HCQ following 8 weeks of monotherapy with RBV in HCV-infected patients.

Time frame:
24 weeks

Results for this outcome have not been posted.

PrimarySafety: Number of Participants With Adverse Events

Safety was assessed throughout study by collection of adverse event and concomitant medication data, and routine monitoring of lab safety tests, physical exams, ophthalmic examination, vital signs and 12 lead electrocardiograms.

Time frame:
all 24 weeks
Reported as:
Number · participants
Safety: Number of Participants With Adverse Events
participantsRibavirin+HCQ
Safety: Number of Participants With Adverse Events4
SecondaryEfficacy

To evaluate the efficacy of 8 weeks monotherapy with RBV in HCV-infected patients.

Time frame:
8 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ribavirin+HCQ—0/4 (0%)4/4 (100%)
Most frequent other events
Most frequent other events
EventRibavirin+HCQ
AstheniaGastrointestinal disorders2/4
insomniaPsychiatric disorders2/4
Upper abdominal painGastrointestinal disorders1/4
Gastroesophageal reflux diseaseGastrointestinal disorders1/4
HeadacheNervous system disorders1/4
DysgeusiaNervous system disorders1/4
dry eyeEye disorders1/4
DyspneaRespiratory, thoracic and mediastinal disorders1/4
coughRespiratory, thoracic and mediastinal disorders1/4
HypertensionVascular disorders1/4

Baseline characteristics

40 subjects were planned to be included in the study; however, due to the Sponsor's decision, the study was terminated prematurely after 4 subjects had completed the study, due to failure to recruit subjects

Age, Continuous
Age, Continuous(years)Ribavirin+HCQ
Mean57.8 ± 6.0
Age, Categorical
Age, Categorical(Participants)Ribavirin+HCQ
<=18 years0
Between 18 and 65 years4
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Ribavirin+HCQ
Female1
Male3
Region of Enrollment
Region of Enrollment(participants)Ribavirin+HCQ
France4
08

Study locations

2 sites
  • Hospital St. Joseph
    Marseille, France
  • Cochin Hospital
    Paris, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2013
First posted
Apr 17, 2013
Start
Apr 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Aug 28, 2014
Last update
Aug 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01833845
Lead sponsor
BioLineRx, Ltd.
Responsible party
Sponsor
First posted
Apr 17, 2013
Start date
Apr 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Aug 28, 2014
Last update
Aug 28, 2014

Study contacts

Stanislas Pol, MD
principal investigator · Cochin Hospital
Marc Bourliere, MD
principal investigator · S.Joseph Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribavirin · Hydroxychloroquine

Start the discussion